Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
Abbott aims to expand Xience Prime patent for 1.7 years
Stentys closes $1.4M acquisition of Cappella’s Peel Away stent delivery device
Stentys said it’s closed the deal on the €1 million ($1.4 million) deal to acquire the Peel Away stent delivery system.
The cash-and-stock deal is the 1st strategic acquisition for Stentys, which makes a line of bare-metal and drug-eluting coronary stents.
FLASH: FDA approves Medtronic’s CoreValve for high-risk patients
Cardiovascular Systems launches COAST heart disease study
Medtronic confirms Corventis buy, expects to close this month
Appeals court upholds Gore win over St. Jude Medical
A federal appeals court today upheld a win for W.L. Gore & Assoc. in a patent war with St. Jude Medical (NYSE:STJ) over heart defect repair technology.
CardiAQ Valve accuses Neovasc of stealing trade secrets for Tiara valve
UPDATED June 6, 2014, with comment from Neovasc.
Boston Scientific launches TAVI registry study for Lotus heart valve
Boston Scientific (NYSE:BSX) said it’s launched a post-market registry study for its Lotus replacement heart valve, aiming to follow patients implanted with the transcatheter aortic heart valve out to 5 years.
Stentys to acquire Cappella Peel Away’s stent delivery device
Stentys said it agreed to pay an unspecified amount to acquire Cappella Peel Away and its "novel" stent delivery system.
Princeton, N.J.- and Paris-based Stentys said it plans to integrate the technology into the delivery system for its line of bare-metal and drug-eluting stents, aiming to have the new system on the market in 2015.
Less-sick patients may benefit from preventive ICDs, study says | MassDevice.com On Call
MASSDEVICE ON CALL — New data on implantable cardioverter defibrillators suggests that devices may help even less-sick patients prolong their lives.
The implants are generally indicated for patients who have fairly severe deficiencies in the heart’s left ventricle’s ability to pump blood coming from the left atrium out to the aorta. Normal left ventricular ejection fraction, or LVEF, is generally defined as between 50%-70%. Lower rates are considered a sign of potential dysfunction or heart failure.